Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC

NCT03778138 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Non-squamous Cell Non-Small Cell Lung Cancer

Interventions

DRUG: Anlotinib plus Pemetrexed

Sponsor

Henan Provincial People's Hospital

Collaborators

[object Object]